These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 10967712)

  • 1. Similarities and/or dissimilarities of CYP2D6 polymorphism in three Tunisian ethnic groups: Arabs, Berbers, Numides.
    Attitallah S; Berard M; Belkahia C; Bechtel YC; Bechtel PR
    Therapie; 2000; 55(3):355-60. PubMed ID: 10967712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of N-acetyltransferase (NAT2) in three ethnic groups in Tunisia.
    Attitallah S; Bechtel YC; Belkahia C; Bechtel PR
    Therapie; 2000; 55(3):361-9. PubMed ID: 10967713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans.
    Llerena A; Dorado P; Ramírez R; González I; Alvarez M; Peñas-Lledó EM; Pérez B; Calzadilla LR
    Pharmacogenomics J; 2012 Apr; 12(2):176-83. PubMed ID: 21135868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [CYP2D6 gene polymorphism in psychiatric patients resistant to standard pharmacotherapy].
    Zabrocka M; Woszczek G; Borowiec M; Rabe-Jabłońska J; Kowalski ML
    Psychiatr Pol; 1999; 33(1):91-100. PubMed ID: 10786218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
    LLerena A; de la Rubia A; Berecz R; Dorado P
    Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevalence of ultraextensive drug metabolizers in Croatian population--long-PCR based detection of amplified CYP2D6 gene].
    Bozina N; Tramisak I; Granić P; Puljević D; Stavljenić-Rukavina A
    Lijec Vjesn; 2002; 124(3-4):63-6. PubMed ID: 18958918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH.
    Ozdemir M; Crewe KH; Tucker GT; Rostami-Hodjegan A
    J Clin Pharmacol; 2004 Dec; 44(12):1398-404. PubMed ID: 15545311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug extrapyramidal side-effects or not: is there a dextromethorphan phenotype difference?
    Vandel P; Haffen E; Vandel S; Bonin B; Sechter D; Bizouard P; Dalery J
    Therapie; 2000; 55(3):349-53. PubMed ID: 10967711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of dextromethorphan oxidation in Polish population.
    Skretkowicz J; Wojtczak A; Rychlik-Sych M
    Acta Pol Pharm; 2008; 65(5):611-5. PubMed ID: 19051610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphism of CYP2D6 in Karnataka and Andhra Pradesh population in India.
    Abraham BK; Adithan C; Kiran PU; Asad M; Koumaravelou K
    Acta Pharmacol Sin; 2000 Jun; 21(6):494-8. PubMed ID: 11360682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 phenotypes among Malays in Malaysia.
    Ismail R; Hussein A; Teh LK; Nizam Isa M
    J Clin Pharm Ther; 2000 Oct; 25(5):379-83. PubMed ID: 11123490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2D6 polymorphism in systemic lupus erythematosus patients.
    Kortunay S; Bozkurt A; Bathum L; Basci NE; Calgüneri M; Brøsen K; Kayaalp SO
    Eur J Clin Pharmacol; 1999 Mar; 55(1):21-5. PubMed ID: 10206080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.
    Dalén P; Dahl ML; Eichelbaum M; Bertilsson L; Wilkinson GR
    Pharmacogenetics; 1999 Dec; 9(6):697-706. PubMed ID: 10634132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical importance of genetic polymorphism of drug oxidation.
    Edeki T
    Mt Sinai J Med; 1996; 63(5-6):291-300. PubMed ID: 8898530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
    Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
    Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico.
    Sosa-Macías M; Elizondo G; Flores-Pérez C; Flores-Pérez J; Bradley-Alvarez F; Alanis-Bañuelos RE; Lares-Asseff I
    J Clin Pharmacol; 2006 May; 46(5):527-36. PubMed ID: 16638736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CYP2D6*4 variant in bladder cancer susceptibility in Tunisian patients.
    Ouerhani S; Marrakchi R; Bouhaha R; Ben Slama MR; Sfaxi M; Ayed M; Chebil M; El Gaaied AB
    Bull Cancer; 2008 Feb; 95(2):E1-4. PubMed ID: 18304900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
    Halling J; Weihe P; Brosen K
    Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine.
    Bernal ML; Sinues B; Johansson I; McLellan RA; Wennerholm A; Dahl ML; Ingelman-Sundberg M; Bertilsson L
    Pharmacogenetics; 1999 Oct; 9(5):657-60. PubMed ID: 10591547
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.